Jeff Yass’s KalVista Pharmaceuticals KALV Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | – | Sell |
-46,760
| Closed | -$941K | – | 13989 |
|
|
2026
Q1 | $941K | Sell |
46,760
-25,135
| -35% | -$405K | ﹤0.01% | 8023 |
|
|
2025
Q4 | $1.16M | Sell |
71,895
-321,444
| -82% | -$4.26M | ﹤0.01% | 6849 |
|
|
2025
Q3 | $4.79M | Buy |
393,339
+99,141
| +34% | +$1.37M | ﹤0.01% | 4156 |
|
|
2025
Q2 | $3.33M | Buy |
294,198
+242,030
| +464% | +$2.96M | ﹤0.01% | 4753 |
|
|
2025
Q1 | $602K | Buy |
52,168
+22,990
| +79% | +$235K | ﹤0.01% | 8495 |
|
|
2024
Q4 | $247K | Buy |
29,178
+11,357
| +64% | +$118K | ﹤0.01% | 10240 |
|
|
2024
Q3 | $206K | Buy |
17,821
+4,335
| +32% | +$54.5K | ﹤0.01% | 10409 |
|
|
2024
Q2 | $159K | Sell |
13,486
-6,400
| -32% | -$74.7K | ﹤0.01% | 10637 |
|
|
2024
Q1 | $236K | Sell |
19,886
-7,085
| -26% | -$94.5K | ﹤0.01% | 10244 |
|
|
2023
Q4 | $330K | Buy |
26,971
+16,177
| +150% | +$147K | ﹤0.01% | 9630 |
|
|
2023
Q3 | $104K | Sell |
10,794
-49,177
| -82% | -$502K | ﹤0.01% | 10878 |
|
|
2023
Q2 | $540K | Buy |
59,971
+25,906
| +76% | +$239K | ﹤0.01% | 8133 |
|
|
2023
Q1 | $268K | Sell |
34,065
-73,180
| -68% | -$546K | ﹤0.01% | 9971 |
|
|
2022
Q4 | $725K | Buy |
+107,245
| New | +$574K | ﹤0.01% | 6935 |
|
|
2022
Q2 | – | Sell |
-12,558
| Closed | -$139K | – | 13435 |
|
|
2022
Q1 | $185K | Sell |
12,558
-17,865
| -59% | -$257K | ﹤0.01% | 11325 |
|
|
2021
Q4 | $402K | Sell |
30,423
-10,449
| -26% | -$166K | ﹤0.01% | 9761 |
|
|
2021
Q3 | $713K | Buy |
40,872
+2,819
| +7% | +$57.1K | ﹤0.01% | 8455 |
|
|
2021
Q2 | $912K | Sell |
38,053
-27,967
| -42% | -$732K | ﹤0.01% | 8017 |
|
|
2021
Q1 | $1.7M | Sell |
66,020
-9,563
| -13% | -$251K | ﹤0.01% | 6321 |
|
|
2020
Q4 | $1.44M | Buy |
+75,583
| New | +$1.3M | ﹤0.01% | 5840 |
|
|
2019
Q3 | – | Sell |
-23,514
| Closed | -$521K | – | 10512 |
|
|
2019
Q2 | $521K | Sell |
23,514
-24,546
| -51% | -$576K | ﹤0.01% | 7178 |
|
|
2019
Q1 | $1.38M | Buy |
48,060
+239
| +0.5% | +$5.18K | ﹤0.01% | 4387 |
|
|
2018
Q4 | $944K | Buy |
+47,821
| New | +$961K | ﹤0.01% | 4793 |
|
|
2016
Q3 | – | Sell |
-4,583
| Closed | -$43K | – | 8727 |
|
|
2016
Q2 | $43K | Buy |
+4,583
| New | +$53.1K | ﹤0.01% | 8272 |
|
Other funds holding KALV
Jeff Yass's KALV Position: Q2 2026 in Review
Jeff Yass sold out of KalVista Pharmaceuticals (KALV) in Q2 2026, closing a stake of 46,760 shares — an estimated $941K sold.
Jeff Yass first reported a position in KALV in Q2 2016 and held it in 24 quarters. The position peaked at $4.79M in Q3 2025. 1 fund tracked by Wall St. Rank holds KALV as of Q2 2026.
- Jeff Yass reported no remaining KalVista Pharmaceuticals position as of Q2 2026 after selling out during the quarter.
- Jeff Yass sold 46,760 KalVista Pharmaceuticals shares in Q2 2026, an estimated $941K.
- Jeff Yass first reported a position in KalVista Pharmaceuticals in Q2 2016 and held it in 24 quarters.
- Jeff Yass's KalVista Pharmaceuticals position peaked at $4.79M in Q3 2025.
- 1 fund tracked by Wall St. Rank held KalVista Pharmaceuticals as of Q2 2026.
Based on Susquehanna International Group's 13F filing for Q2 2026, filed 14 Aug 2026.